Cipher Pharmaceuticals Stock Net Income
| CPH Stock | CAD 14.51 0.30 2.03% |
As of the 30th of January, Cipher Pharmaceuticals shows the Risk Adjusted Performance of 0.0128, mean deviation of 1.42, and Downside Deviation of 2.19. Cipher Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cipher Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.6212 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 13.3 M | 13.9 M | |
| Net Income From Continuing Ops | 13.3 M | 8.4 M | |
| Net Income Applicable To Common Shares | 13.3 M | 7.8 M | |
| Net Income Per Share | 0.42 | 0.44 | |
| Net Income Per E B T | 3.52 | 3.69 |
Cipher | Net Income |
Evaluating Cipher Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cipher Pharmaceuticals's fundamental strength.
Latest Cipher Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Cipher Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cipher Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Cipher Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cipher Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cipher Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 11.54 M | 10 Years Trend |
|
Net Income |
| Timeline |
Cipher Net Income Regression Statistics
| Arithmetic Mean | 4,581,243 | |
| Geometric Mean | 6,802,323 | |
| Coefficient Of Variation | 327.53 | |
| Mean Deviation | 9,990,458 | |
| Median | 4,403,000 | |
| Standard Deviation | 15,004,810 | |
| Sample Variance | 225.1T | |
| Range | 65.8M | |
| R-Value | 0.47 | |
| Mean Square Error | 187.4T | |
| R-Squared | 0.22 | |
| Significance | 0.06 | |
| Slope | 1,393,163 | |
| Total Sum of Squares | 3602.3T |
Cipher Net Income History
Cipher Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cipher Pharmaceuticals is extremely important. It helps to project a fair market value of Cipher Stock properly, considering its historical fundamentals such as Net Income. Since Cipher Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cipher Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cipher Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cipher Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cipher Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cipher Pharmaceuticals.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Cipher Pharmaceuticals on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Cipher Pharmaceuticals or generate 0.0% return on investment in Cipher Pharmaceuticals over 90 days. Cipher Pharmaceuticals is related to or competes with Canopy Growth, OrganiGram Holdings, TerrAscend Corp, Aurora Cannabis, Spectral Med, NervGen Pharma, and High Tide. Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada More
Cipher Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cipher Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cipher Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.19 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 12.39 | |||
| Value At Risk | (2.50) | |||
| Potential Upside | 3.49 |
Cipher Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cipher Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cipher Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Cipher Pharmaceuticals historical prices to predict the future Cipher Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0128 | |||
| Jensen Alpha | 0.0016 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0636 |
Cipher Pharmaceuticals January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0128 | |||
| Market Risk Adjusted Performance | 0.0736 | |||
| Mean Deviation | 1.42 | |||
| Semi Deviation | 2.08 | |||
| Downside Deviation | 2.19 | |||
| Coefficient Of Variation | 11646.42 | |||
| Standard Deviation | 2.12 | |||
| Variance | 4.51 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0016 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0636 | |||
| Maximum Drawdown | 12.39 | |||
| Value At Risk | (2.50) | |||
| Potential Upside | 3.49 | |||
| Downside Variance | 4.78 | |||
| Semi Variance | 4.34 | |||
| Expected Short fall | (1.53) | |||
| Skewness | (0.52) | |||
| Kurtosis | 4.93 |
Cipher Pharmaceuticals Backtested Returns
Cipher Pharmaceuticals secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of risk over the last 3 months. Cipher Pharmaceuticals exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cipher Pharmaceuticals' Downside Deviation of 2.19, risk adjusted performance of 0.0128, and Mean Deviation of 1.42 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cipher Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cipher Pharmaceuticals is expected to be smaller as well. At this point, Cipher Pharmaceuticals has a negative expected return of -0.0029%. Please make sure to confirm Cipher Pharmaceuticals' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Cipher Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.01 |
Very weak reverse predictability
Cipher Pharmaceuticals has very weak reverse predictability. Overlapping area represents the amount of predictability between Cipher Pharmaceuticals time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cipher Pharmaceuticals price movement. The serial correlation of -0.01 indicates that just 1.0% of current Cipher Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.01 | |
| Spearman Rank Test | 0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cipher Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cipher Pharmaceuticals reported net income of 11.54 M. This is 96.62% lower than that of the Pharmaceuticals sector and 103.0% lower than that of the Health Care industry. The net income for all Canada stocks is 97.98% higher than that of the company.
Cipher Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in net income category among its peers.
Cipher Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cipher Pharmaceuticals from analyzing Cipher Pharmaceuticals' financial statements. These drivers represent accounts that assess Cipher Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cipher Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 37.2M | 71.2M | 106.4M | 246.0M | 221.4M | 232.5M | |
| Enterprise Value | 17.2M | 42.8M | 66.9M | 268.7M | 241.9M | 254.0M |
Cipher Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.053 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 382.48 M | ||||
| Shares Outstanding | 25.37 M | ||||
| Shares Owned By Insiders | 42.57 % | ||||
| Shares Owned By Institutions | 1.31 % | ||||
| Number Of Shares Shorted | 40.73 K | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.43 X | ||||
| Price To Sales | 7.36 X | ||||
| Revenue | 33.36 M | ||||
| Gross Profit | 37.2 M | ||||
| EBITDA | 11.87 M | ||||
| Net Income | 11.54 M | ||||
| Cash And Equivalents | 17.84 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 40.58 M | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 6.08 X | ||||
| Cash Flow From Operations | 19.55 M | ||||
| Short Ratio | 1.38 X | ||||
| Earnings Per Share | 0.91 X | ||||
| Target Price | 19.2 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 368.46 M | ||||
| Total Asset | 162.51 M | ||||
| Retained Earnings | 77.65 M | ||||
| Working Capital | 18.61 M | ||||
| Net Asset | 162.51 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.